Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list

Liver International

Volumn 34, Issue 8, 2014, Pages 1176-1183

  Myers, Robert P ^a,b   Tandon, Puneeta ^c   Ney, Michael ^c   Meeberg, Glenda ^c   Faris, Peter ^b   Shaheen, Abdel Aziz M ^a   Aspinall, Alexander I ^a   Burak, Kelly W ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Discrimination; Liver transplantation; MELD; MELDNa; Mortality; Outcomes

Indexed keywords

SERUM ALBUMIN; SODIUM;

5VMELD SCORE; ACUTE LIVER FAILURE; ADULT; ALBUMIN BLOOD LEVEL; ALCOHOL LIVER CIRRHOSIS; ARTICLE; AUTOIMMUNE HEPATITIS; CANADA; CHOLESTASIS; CONTROLLED STUDY; DISEASE ASSOCIATION; END STAGE LIVER DISEASE; FEMALE; HAZARD RATIO; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; HYPOALBUMINEMIA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; STATISTICAL ANALYSIS; SURGICAL MORTALITY; SURGICAL PATIENT; SURVIVAL RATE; VALIDATION STUDY; BLOOD; DECISION SUPPORT SYSTEM; METABOLISM; MIDDLE AGED; MORTALITY; PATIENT SELECTION; STANDARDS;

CANADA; DECISION SUPPORT TECHNIQUES; END STAGE LIVER DISEASE; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; SERUM ALBUMIN; SODIUM; WAITING LISTS;

EID: 84905736578     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12373     Document Type: Article

References (33)

1. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
2. Brown RS Jr, Lake JR. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant 2005; 5: 203-4.
3. Wiesner RH. Evidence-based evolution of the MELD/PELD liver allocation policy. Liver Transpl 2005; 11: 261-3.
4. Bambha KM, Biggins SW. Inequities of the Model for End-Stage Liver Disease: an examination of current components and future additions. Curr Opin Organ Transplant 2008; 13: 227-33.
5. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS. Re-weighting the model for end-stage liver disease score components. Gastroenterology 2008; 135: 1575-81.
6. Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. J Hepatol 2011; 54: 462-70.
7. Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46: 520-7.
8. Huo SC, Huo TI, Lin HC, et al. Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation 2007; 84: 1406-12.
9. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018-26.
10. Huo TI, Wang YW, Yang YY, et al. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int 2007; 27: 498-506.
11. Myers RP, Shaheen AA, Faris P, Aspinall AI, Burak KW. Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list. PLoS ONE 2013; 8: e51926.
12. Kizilisik TA, Larsen IM, Bain VG, Kneteman NM. Liver transplantation at the University of Alberta Hospitals: a review of the first three years. Transplant Proc 1993; 25: 2203-5.
13. Bazarah SM, Peltekian KM, McAlister VC, Bitter-Suermann H, MacDonald AS. Utility of MELD and Child-Turcotte-Pugh scores and the Canadian waitlisting algorithm in predicting short-term survival after liver transplant. Clin Invest Med 2004; 27: 162-7.
14. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805.
15. Therneau TM, Grambsch PM. Modeling survival data: Extending the Cox model. New York, NY: Springer-Verlag, 2000.
16. D'Agostino RB, Nam BH. Evaluation of the performance of survival analysis models: discrimination and calibration measures. In: Balakrishnan N, Rao CR, eds. Advances in survival analysis. Amsterdam: Elsevier, 2004; 1-25.
17. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005; 61: 92-105.
18. Kremers WK. Concordance for survival time data: Fixed and time-dependent covariates and possible ties in predictor and time. Technical Report Series #80, April 2007 (http://mayoresearch.mayo.edu/mayo/research/biostat/upload/80.pdf). Accessed November 1, 2009.
19. Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007; 13: 1174-80.
20. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009; 150: 795-802.
21. Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl 2012; 18: 1209-16.
22. Fernandez J, Gustot T. Management of bacterial infections in cirrhosis. J Hepatol 2012; 56(Suppl 1): S1-12.
23. Zoli M, Cordiani MR, Marchesini G, et al. Prognostic indicators in compensated cirrhosis. Am J Gastroenterol 1991; 86: 1508-13.
24. Merkel C, Bolognesi M, Angeli P, et al. Prognostic indicators of survival in patients with cirrhosis and esophageal varices, without previous bleeding. Am J Gastroenterol 1989; 84: 717-22.
25. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
26. Realdi G, Fattovich G, Hadziyannis S, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21: 656-66.
27. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217-31.
28. Schaubel DE, Guidinger MK, Biggins SW, et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9(4 Pt 2): 970-81.
29. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM. Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg 2003; 237: 319-34.
30. Doumas BT, Peters T Jr. Serum and urine albumin: a progress report on their measurement and clinical significance. Clin Chim Acta 1997; 258: 3-20.
31. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol green. Clin Chim Acta 1971; 31: 87-96.
32. Doumas BT, Peters T Jr. Origins of dye-binding methods for measuring serum albumin. Clin Chem 2009; 55: 583-4.
33. McDiarmid SV, Anand R, Lindblad AS. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation 2002; 74: 173-81.